COL17A1 and diabetes mellitus: These findings demonstrated that even in the absence of clinical BP, patients with DM + DPP4i can develop autoantibodies against diverse BP180 epitopes—including the NC7-Col4 region—highlighting a preclinical humoral response that may presage DPP4i-BP development.